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Insulin-independent glucose disposal (referred to as glucose effectiveness [GE]) is crucial for glucose homeo-
stasis and, until recently, was thought to be invariable. However, GE is reduced in type 2 diabetes and mark-
edly decreased in leptin-deficient ob/ob mice. Strategies aimed at increasing GE should therefore be capable 
of improving glucose tolerance in these animals. The gut-derived hormone FGF19 has previously been shown 
to exert potent antidiabetic effects in ob/ob mice. In ob/ob mice, we found that systemic FGF19 administration 
improved glucose tolerance through its action in the brain and that a single, low-dose i.c.v. injection of FGF19 
dramatically improved glucose intolerance within 2 hours. Minimal model analysis of glucose and insulin 
data obtained during a frequently sampled i.v. glucose tolerance test showed that the antidiabetic effect of 
i.c.v. FGF19 was solely due to increased GE and not to changes of either insulin secretion or insulin sensitivity. 
The mechanism underlying this effect appears to involve increased metabolism of glucose to lactate. Together, 
these findings implicate the brain in the antidiabetic action of systemic FGF19 and establish the brain’s capac-
ity to rapidly, potently, and selectively increase insulin-independent glucose disposal.
Introduction
In addition to insulin secretion and insulin sensitivity (Si), insu-
lin-independent mechanisms are critical to normal glucose 
homeostasis (1). Given that such mechanisms contribute at least 
as much to normal glucose tolerance as does insulin itself (1), it is 
surprising how little is known about them. This lack of research 
interest can be traced to the widespread perception of insu-
lin-independent glucose disposal, which has been termed glucose 
effectiveness (GE; the ability of glucose to promote its own dis-
posal, independently of insulin), as the fixed, obligate, and unreg-
ulated mechanism whereby insulin-insensitive tissues meet ongo-
ing fuel needs. Yet glucose intolerance and type 2 diabetes (T2D) 
are characterized by decreases of GE as well as of insulin secretion 
and action (1). In leptin-deficient ob/ob mice, for example, GE was 
shown recently to be reduced by approximately 70%, based on min-
imal model analysis of data obtained from a frequently sampled 
i.v. glucose tolerance test (FSIGT) (2). Based on its importance to 
glucose homeostasis, we hypothesized that any intervention capa-
ble of normalizing glucose tolerance in these mice should do so, at 
least in part, by increasing GE.
FGF19 and its rodent homolog, FGF15, is one of three mem-
bers of the family of hormonal FGFs. FGF19 is secreted by 
enterocytes located in the distal small intestine following acti-
vation of the nuclear bile acid receptor, FXR, by bile acid bind-
ing (3). In addition to its well-established role in the negative 
feedback control of hepatic bile acid synthesis (4, 5), FGF19 
exerts potent antidiabetic effects in rodent models, including 
ob/ob mice (6). Similarly, transgenic overexpression of FGF19 
improves glucose tolerance in diet-induced obese mice (6, 7), 
whereas FGF15-deficient mice display impaired glucose toler-
ance that is corrected by FGF19 administration (8).
Although initially thought to act primarily via FGFR4 receptors 
in the liver, the antidiabetic effects of FGF19 appear to involve 
a different FGF receptor subtype, because they are preserved in 
FGFR4-deficient mice (9). Instead, several findings implicate 
FGFR1 in this effect. First, systemic administration of a FGF19 
variant that activates FGFR1 but not FGFR4 ameliorates diabe-
tes in ob/ob mice, while this effect is absent for a FGF19 variant 
that activates FGFR4 but not FGFR1 (10). Second, the potent glu-
cose-lowering effect of FGF19 is mimicked by monoclonal anti-
bodies that selectively activate a specific FGFR1 isoform (FGFR1c) 
(11). Although activation of FGFR1 in peripheral tissues, such as 
brown and white adipose tissue, may contribute to glucose low-
ering, this receptor is also expressed in mediobasal hypothalamic 
areas involved in glucose homeostasis (12, 13), and administra-
tion of FGF19 directly into the brain improves glucose tolerance 
in both ob/ob mice (6) and diet-induced obese rats (14).
The current studies were undertaken to determine whether the 
antidiabetic effect of systemically administered FGF19 involves a 
central site of action and, if so, to determine the contribution(s) 
made by insulin-dependent and -independent mechanisms to this 
effect. We report that, in ob/ob mice, the glucose-lowering effect of 
systemic FGF19 is reduced by approximately 50% when its action 
in the brain is blocked by i.c.v. administration of an FGFR antag-
onist. Thus, the brain plays a key role in the antidiabetic effects of 
this hormone. To investigate how FGF19 action in the brain affects 
systemic glucose metabolism, we performed a FSIGT 2 hours after 
i.c.v. injection of either FGF19 or its vehicle in ob/ob mice as well 
as in vehicle-injected C57BL/6 controls. Glucose and insulin data 
from the FSIGT were analyzed using the minimal model method, 
which has been widely used in humans (1) and was recently vali-
dated in mice (including in ob/ob mice) (2), as a tool with which 
to measure insulin secretion, Si, and GE. Surprisingly, we found 
that the potent antidiabetic effect of i.c.v. FGF19 in ob/ob mice did 
not involve increases of either insulin secretion or Si. Instead, the 
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effect was mediated entirely by a 3-fold increase of GE. Further-
more, our data suggest that reduced GE in ob/ob mice is linked 
to reduced glycolysis of glucose to lactate and that FGF19 action 
in the CNS of these animals reverses this defect. Thus, whereas 
insulin-independent glucose lowering has heretofore been con-
sidered invariant, obligate, and unregulated, our findings reveal 
the brain’s inherent capacity to rapidly, potently, and selectively 
increase glucose disposal via this mechanism.
Results
Effect of i.c.v. FGF19 on glucose tolerance in ob/ob mice. Since i.c.v. 
FGF19 can reduce food intake and body weight as well as blood 
glucose levels (6, 14), we initially sought to identify a protocol 
in which effects on glucose metabolism are not confounded by 
changes of energy balance. After verifying an earlier report (6) 
showing that chronic (i.e., over 6 days) i.c.v. administration of 
FGF19 exerts potent glucose lowering in ob/ob mice (data not 
shown), we asked whether this effect can be detected following just 
a single i.c.v. injection of FGF19, with food removed during the 
interval (1.5 hours) between i.c.v. injection and glucose tolerance 
testing. We found that, in ob/ob mice (mean body weight: 49.8 ± 
1.2 g), i.c.v. injection of FGF19 lowered fasting blood glucose levels 
(P < 0.05) and dose-dependently improved glucose tolerance rela-
tive to that of vehicle-treated controls (P < 0.05) (Figure 1, A and B). 
Since the mice did not have access to food following i.c.v. injec-
tion, the observed effects were not due to changes of food intake or 
body composition, nor were they due to leakage of FGF19 into the 
periphery, since systemic administration at the same low dose had 
no effect on these parameters (Figure 1, C and D). Thus, FGF19 
action in the brain induces glucose lowering via a mechanism that 
is unrelated to changes of energy balance.
Role of the brain in the response to systemic FGF19. Most studies of 
the antidiabetic effect of FGF19 have focused on effects in periph-
eral tissues. To determine whether the brain also plays a role, we 
asked whether the response to systemic FGF19 is attenuated by 
central administration of an FGF receptor inhibitor (PD173074). 
Prior to undertaking this study, we verified that, when given i.c.v., 
the inhibitor blocks the response to i.c.v. FGF19. Consistent with 
our earlier observations, a single i.c.v. injection of FGF19 lowered 
fasting blood glucose levels and significantly improved i.p. glucose 
tolerance in ob/ob mice that received an i.c.v. vehicle pretreatment 
injection, and, as expected, this beneficial effect was fully blocked 
by i.c.v. pretreatment with PD173074 at a dose that had no effect 
when given alone (Figure 2, A and B).
We next asked whether i.c.v. pretreatment with the FGFR inhib-
itor affects glucose lowering induced by systemic administration 
of FGF19 at a dose far higher than what is needed when given i.c.v. 
(1 mg/kg vs. 3 μg). As expected, systemic administration of FGF19 
lowered fasting blood glucose levels and improved glucose toler-
ance in ob/ob mice relative to that of vehicle-treated controls. Since 
this effect was attenuated by approximately 50% by i.c.v. pretreat-
ment with PD173074 (Figure 2, C and D), the glucose-lowering 
effect of systemic FGF19 appears to be mediated at least in part 
via a central mechanism.
Effect of i.c.v. FGF19 on determinants of i.v. glucose tolerance in ob/ob 
mice. Having established a role for the brain in the antidiabetic 
effect of FGF19, we next sought to investigate underlying mecha-
nisms. To this end, we used the FSIGT protocol that, having been 
used in human studies for many years (1), was recently validated for 
use in mice, including ob/ob mice (2). Analysis of glucose and insu-
lin data from the FSIGT using the minimal model provides quan-
titative estimates of insulin secretion, GE, Si, and the disposition 
index (a measure of the ability of β cells to compensate for insulin 
resistance). Three groups of mice were studied: ob/ob mice treated 
with a single i.c.v. injection FGF19 (3 μg) or its vehicle (mean body 
weight: 44.2 ± 0.8 g) and WT C57BL/6 control mice that received 
i.c.v. vehicle (weight: 25.1 ± 0.5 g). This approach allowed us to 
determine (a) whether the glucoregulatory effects of central FGF19 
in ob/ob mice are due to increases of insulin secretion, insulin 
action, or insulin-independent glucose disposal and (b) the extent 
to which glucose tolerance of ob/ob mice was normalized follow-
ing a single i.c.v. injection of FGF19. While fasting blood glucose 
Figure 1
Effect on glucose tolerance of a single injection FGF19 
given either centrally or systemically to ob/ob mice.  
(A and C) Glucose tolerance (0.5 g/kg) and (B and D) 
the integrated area under the glucose curve (AUCglucose) 
in leptin-deficient ob/ob animals that received either 
a single, acute i.c.v. or i.p. injection of FGF19 at either 
1 or 3 μg or its vehicle. Data represent mean ± SEM. 
*P < 0.05 vs. i.c.v. vehicle. #P < 0.05 vs. i.c.v. FGF19 (1 μg).
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levels were similar in i.c.v. vehicle-treated ob/ob and WT mice, 
basal plasma insulin levels were markedly elevated in the former 
group, consistent with previous evidence of severe insulin resis-
tance in these animals (2). Similarly, glucose tolerance was mark-
edly impaired in i.c.v. vehicle-treated ob/ob mice relative to that in 
WT controls following an i.v. glucose bolus (Figure 3, A and B), 
despite a markedly increased acute insulin response to glucose 
(a measure of first-phase insulin secretion) and sustained elevation 
of plasma insulin levels throughout the study (Figure 3, C and D).
As expected, this marked impairment of glucose tolerance was 
significantly improved in ob/ob mice that received FGF19 (P < 0.05) 
(Figure 3, A and B). Based on the area under the glucose curve, i.c.v. 
FGF19 treatment corrected the abnormality of glucose tolerance of 
ob/ob mice by 65% (P < 0.05). Therefore, within 2 hours of a single 
i.c.v. injection FGF19 dramatically improved glucose tolerance in 
ob/ob mice. As this improvement occurred despite no difference in 
plasma insulin levels at any time during the glucose tolerance test 
(Figure 3, C and D), it cannot be attributed to increased insulin 
secretion. We therefore turned our attention to its effects on the 
two other determinants of glucose tolerance, Si and insulin-inde-
pendent glucose disposal. As expected (2), minimal model analysis 
of glucose and insulin data from the FSIGT revealed the Si index to 
be markedly reduced in i.c.v. vehicle-treated ob/ob mice relative to 
that in WT controls (Figure 3E). Unexpectedly, however, i.c.v. FGF19 
injection had no effect on Si in ob/ob mice. Thus, the observed 
improvement of glucose tolerance mediated by i.c.v. FGF19 was not 
due to increased Si (Figure 3E), and since insulin secretion was sim-
ilarly unaffected, the improvement was also not associated with an 
increase of the disposition index (data not shown).
As previously reported (2), GE (defined as the ability of an 
increased concentration of glucose to promote its own disposal 
at basal insulin) was reduced by approximately 80% in i.c.v. vehi-
cle-treated ob/ob mice relative to that in WT mice (Figure 3F). 
Given the importance of GE as a determinant of glucose tolerance 
(1), this decrease undoubtedly plays a major role in the impaired 
glucose homeostasis of ob/ob mice. This assertion in turn predicts 
that an increase of GE has the potential to explain the beneficial 
effect of central FGF19. Consistent with this prediction, we found 
that i.c.v. FGF19 induced a 3-fold increase of GE, such that it was 
almost completely normalized (Figure 3F). Thus, the effect of i.c.v. 
FGF19 to improve glucose tolerance in ob/ob mice results primar-
ily from a marked increase of GE. Under the influence of FGF19, 
therefore, the brain has the capacity to rapidly, potently, and selec-
tively increase insulin-independent glucose disposal.
As a first step to better understand how the CNS action of FGF19 
action increases GE, we measured plasma lactate levels during the 
FSIGT, as described in Figure 3. Previous work has shown that, 
in response to a glucose challenge, plasma lactate levels increase 
as a consequence of glucose uptake into tissues (primarily liver), 
followed by glycolysis to lactate that is subsequently released into 
the circulation. Since both GE and the plasma lactate response to 
glucose are reduced in obese individuals (15–17), we considered 
the possibility that, in ob/ob mice, reduced GE is causally linked 
to decreased metabolism of injected glucose to lactate. Consistent 
with this hypothesis, we found that, as in normal humans and dogs 
(17), the plasma lactate level increased rapidly but transiently fol-
lowing an i.v. glucose challenge in WT mice (Figure 4, A and B) and 
that this effect was blunted in vehicle-treated ob/ob mice (Figure 4, 
A and B). Indeed, lactate levels did not increase at all in these ani-
mals, whereas in ob/ob mice receiving i.c.v. FGF19, the plasma lac-
tate response to i.v. glucose increased markedly (Figure 4, A and B), 
as did GE (Figure 3).
To determine whether the effect of FGF19 to increase GE 
involves reductions of either plasma glucagon or nonesterified 
fatty acid (FFA) levels, we perf utes: 340 ± 51 mg/dl for vehicle vs. 
241 ± 34 mg/dl for FGF19; P < 0.05). However, the glucose-lower-
ing effect of FGF19 was not associated with significant changes in 
the plasma level of either glucagon or FFAs (Figure 4, C and D).
Liver parameters. As a first step to investigate whether changes 
of liver glucose metabolism contributed to the glucose-lowering 
effect of i.c.v. FGF19, we measured baseline liver glycogen and tri-
glyceride content as well as hepatic expression of gluconeogenic 
Figure 2
Effect of a centrally administered FGF receptor blocker 
on the glucose-lowering effect of FGF19. (A and C) Glu-
cose tolerance (0.5 g/kg) and (B and D) the change in the 
integrated area under the glucose curve in leptin-deficient 
ob/ob mice that received either an i.c.v. pretreatment injec-
tion of the FGFR inhibitor, PD173074 (25 μg), or its vehicle 
(veh) 1-hour prior to either systemic or central administration 
of FGF19 or its vehicle. Animals were then subject to an ipgtt 
(0.5 g/kg) 90 minutes later. Data represent mean ± SEM. 
*P < 0.05 vs. i.c.v. vehicle–i.c.v./i.p. vehicle.
research article
4802 The Journal of Clinical Investigation   http://www.jci.org   Volume 123   Number 11   November 2013
genes in the absence of a glucose challenge. Our data show that 
while hepatic levels of G6Pase were significantly reduced in ob/ob 
mice treated with i.c.v. FGF19 relative to vehicle-treated ob/ob and 
WT controls, there were no differences in hepatic Pepck mRNA 
levels or in either liver glycogen or triglyceride content (Figure 5).
To determine whether the effect of i.c.v. FGF19 to enhance dis-
posal of a glucose load is associated with increased liver glycogen 
content, as expected if the mechanism involves increased liver glu-
cose uptake and glycogen synthesis, we measured liver glycogen 
content 30 minutes after an i.p. glucose bolus (0.5 g/kg) in ob/ob 
mice that had received i.c.v. injection of either vehicle or FGF19 
(3 μg) 2 hours earlier. Consistent with our previous observations, 
central FGF19 administration reduced blood glucose levels relative 
to those of vehicle-treated controls both at baseline and 30 min-
utes after the glucose bolus (baseline: 179 ± 31 mg/dl for vehicle 
vs. 106 ± 26 mg/dl for FGF19; P < 0.05; 30 minutes: 330 ± 46 mg/dl 
for vehicle vs. 243 ± 5 mg/dl for FGF19; P < 0.05). However, the 
glucose-lowering effect of FGF19 was not associated with a sig-
nificant increase in hepatic glycogen levels (8.83 ± 0.57 mg/g tissue 
for vehicle vs. 8.60 ± 1.17 mg/g tissue for FGF19; P = NS). We next 
examined whether hepatic glycogen levels are increased following 
an i.p. glucose bolus in ob/ob animals that receive systemic (rather 
than central) FGF19 (1 mg/kg i.p.). Again, the glucose-lowering 
effect of FGF19 was not associated with a significant change of 
hepatic glycogen levels (9.66 ± 0.93 mg/g tissue for vehicle vs. 9.37 
± 0.37 mg/g tissue for FGF19; P = NS). These results indicate that, 
in ob/ob mice, the effect of FGF19 to improve glucose tolerance, 
selectively increase GE, and raise plasma lactate levels occurs 
despite no change in liver glycogen content.
Role of melanocortin signaling in glucoregulatory effects of i.c.v. FGF19. 
As the melanocortin pathway is implicated in central regulation 
of glucose metabolism by leptin (18, 19), insulin (20, 21), and glu-
cose, we asked whether (a) FGF19 activates proopiomelanocortin 
(POMC) neurons in the arcuate nucleus (as judged by induction 
of c-Fos staining) and (b) whether intact melanocortin signaling 
is required for the glucose-lowering effect of i.c.v. FGF19. To facil-
itate detection of c-Fos immunoreactivity in POMC neurons, we 
studied the effect of i.c.v. FGF19 in C57BL/6 mice in which POMC 
cells are fluorescently labeled (Pomc-Tau-GFP mice). As depicted 
in Figure 6, there was no effect of i.c.v. FGF19 to induce c-Fos in 
labeled POMC cells relative to i.c.v. vehicle-treated controls.
To determine whether melanocortin signaling is required 
for the glucose-lowering effects of central FGF19, we asked 
whether it lowers fasting blood glucose levels or improves 
glucose tolerance in melanocortin-4 receptor–deficient 
(Mc4r-deficient) mice. Indeed, i.c.v. FGF19 clearly exerts a glu-
cose-lowering action in these animals relative to that in i.c.v. 
vehicle-treated animals (P < 0.05) (Figure 6, C and D). Therefore, 
Figure 3
Effect of FGF19 on determinants of glucose tolerance 
in ob/ob mice. (A) Blood glucose, (B) the integrated 
area under the glucose curve, (C) plasma insulin lev-
els, (D) the acute insulin response to glucose (AIRg), 
(E) Si, and (F) GE in ob/ob mice or littermate controls 
that received either i.c.v. vehicle or FGF19 (3 μg) and 
were subjected to a frequently sampled glucose tol-
erance test. Data represent mean ± SEM. *P < 0.05 
vs. WT i.c.v. vehicle; #P < 0.05 vs. ob/ob i.c.v. vehicle.
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FGF19-induced glucose lowering is mediated at least in part via 
a melanocortin-independent mechanism.
Discussion
Observations made in a rat model of uncontrolled, insulin- 
deficient diabetes suggest that the brain has the capacity to lower 
blood glucose levels via insulin-independent means. Specifically, 
continuous or repeated daily i.c.v. leptin administration can 
normalize elevated blood glucose levels in these animals despite 
persistent, severe insulin deficiency (22–25). Building upon this 
initial finding, we hypothesized that, since the insulin-indepen-
dent component of glucose tolerance, GE, is markedly reduced in 
ob/ob mice, this defect will be remedied by FGF19 (2), because it has 
potent antidiabetic effects in these animals. We further hypothe-
sized that since FGF19 is effective following either peripheral or 
low-dose central administration in these animals (6), its effect to 
increase GE is mediated centrally. Our finding that glucose low-
ering induced by systemic FGF19 administration in ob/ob mice is 
attenuated by central administration of an inhibitor of FGF recep-
tors implicates the brain in this effect. Moreover, centrally admin-
istered FGF19 improves glucose tolerance in these animals via a 
mechanism that cannot be explained by changes of insulin secre-
tion or insulin action but arises instead from a 3-fold increase of 
GE. Although a detailed understanding of mechanisms mediating 
this effect awaits further study, our data support a model in which 
central FGF19 increases GE by stimulating glycolysis of glucose 
to lactate and in which the neuronal systems involved are at least 
partially independent of melanocortin signaling. Taken together, 
these data implicate the CNS in the glucose-lowering effect of 
FGF19 and, to our knowledge, are the first to establish the ability 
of the brain to improve glucose tolerance by rapidly, potently, and 
selectively increasing insulin-independent glucose disposal. These 
findings therefore establish the existence of a novel brain mecha-
nism for insulin-independent control of blood glucose levels.
Growing evidence suggests that the CNS plays a key role in the 
regulation of glucose homeostasis. In obese rodents, increased 
hypothalamic input from hormonal (i.e., insulin and leptin) 
or nutrient-related (i.e., FFA) signals improves hepatic Si via a 
mechanism involving vagal input to the liver, whereas disruption 
of this hypothalamic input causes insulin resistance (26–30). In 
addition to these effects, the recent finding that continuous i.c.v. 
infusion of leptin completely normalizes glycemia in rats with 
streptozotocin-induced diabetes (22–25) suggests that the brain 
has the capacity to potently lower glucose levels via mechanisms 
that are insulin independent. To investigate the hypothesis that 
FGF19 has the capacity to lower blood glucose by mechanisms 
that are insulin independent, we used minimal model analysis of 
glucose and insulin data from a FSIGT, an approach developed 
in humans and recently validated for use in mice (2). We found 
that, in ob/ob mice, a single i.c.v. injection of a low dose of FGF19 
improved glucose tolerance markedly, despite having no effect 
on either insulin secretion or action. The dramatic effect of cen-
trally administered FGF19 to increase GE is remarkable, in that 
with the exception of vigorous exercise (31), there is no precedent 
for rapid upregulation of insulin-independent glucose disposal, 
much less by the brain.
The brain’s inherent capacity to promote glucose lowering 
through insulin-independent mechanisms is novel in the sense 
that previous work in this area has focused largely on hypothalamic 
control of hepatic Si (32, 33). That insulin-independent effects were 
not identified in such studies could reflect the fact that the meth-
ods used are not optimized to detect them. The euglycemic, hyper-
insulinemic clamp method, widely accepted as the “gold standard” 
for quantitative assessment of glucose metabolism and Si, has been 
used extensively in human as well as rodent studies. By comparison, 
although minimal model analysis of FSIGT data has seen wide usage 
in human research, it was only validated for use in mice in the last 
year (2). This method measures not only Si and GE, but also first-
phase insulin secretion and the disposition index (the product of Si 
and insulin secretion, a validated predictor of progression to T2D 
in humans). By comparison, the clamp (but not the minimal model 
analysis) quantifies rates of glucose production and utilization and, 
with some modification, can assess rates of glycogenolysis, gluconeo-
genesis, and glucose uptake into specific (nonhepatic) tissues.
Figure 4
Effect of FGF19 on plasma glucagon, FFA, and lac-
tate levels in ob/ob mice. (A) Plasma lactate levels and 
(B) the integrated area under the lactate curve (AUClactate) 
during the first 20 minutes of the same FSIGT performed 
in WT and ob/ob mice that received either i.c.v. vehicle 
or FGF19 shown in Figure 3. (C) Plasma glucagon and 
(D) FFA levels in ob/ob mice treated with FGF19 
(1 mg/kg i.p.) or its vehicle, followed 90 minutes later by 
an i.p. glucose bolus. Glucagon and FFA levels were mea-
sured in plasma obtained 30 minutes after the glucose 
bolus. Data represent mean ± SEM. *P < 0.05 vs. WT i.c.v. 
vehicle; #P < 0.05 vs. ob/ob i.c.v. vehicle.
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Si is defined in clamp studies as the increase of glucose dis-
posal (or decrease of glucose appearance) observed when insulin 
levels are raised while glucose levels are held constant. Stated 
differently, changes in rates of glucose production or disposal 
measured in the face of high insulin are attributed solely to the 
action of insulin. However, in the event that insulin-indepen-
dent glucose disposal (or insulin-independent suppression of 
hepatic glucose production) is also increased by the interven-
tion under study, the extent to which observed changes are 
attributable to insulin action cannot be known with certainty, 
since some of the glucose infused during the clamp (to maintain 
euglycemia in the presence of high insulin) would have been dis-
posed of via insulin-independent mechanisms. Thus, whether 
insulin-independent mechanisms contributed to some of the 
centrally mediated effects attributed previously to changes of Si 
(32, 33) awaits additional study.
The insulin-independent component of glucose disposal in 
sedentary subjects has historically been considered to be a fixed, 
obligate, and invariant means whereby insulin-independent tissues 
obtain glucose primarily via the process of glucose mass action, by 
which increasing concentrations of glucose passively drive glucose 
into cells in a largely unregulated manner (1). It is for this reason 
that research into mechanisms underlying insulin-independent 
glucose disposal has languished in comparison with the substantial 
effort and progress made toward understanding insulin secretion 
and its action in peripheral tissues. Nevertheless, data from clin-
ical studies performed years ago offer evidence suggestive of reg-
ulation. For one, i.v. infusion of glucagon-like peptide-1 (GLP-1) 
in humans improves i.v. glucose tolerance by increasing GE as 
well as insulin secretion (34), while, conversely, GE was reduced 
following i.v. administration of a somatostatin analog, an effect 
that impairs glucose tolerance beyond what can be explained by 
the associated inhibition of insulin secretion (35). Although the 
mechanism underlying these effects on GE is unknown, our data 
with FGF19 raise the possibility of an action mediated in the brain.
Although our conclusions regarding the role of GE in the 
antidiabetic effect of FGF19 are based primarily on studies con-
ducted in ob/ob mice, we believe that these findings have broader 
implications. First, our findings are compatible with several 
studies showing that, in rodent models of severe insulin-defi-
cient diabetes, leptin administration can fully normalize blood 
glucose levels, despite persistent insulin deficiency (22–25). 
The effect is therefore insulin independent, and, moreover, it 
is mediated centrally, since the effect is observed when leptin is 
given i.c.v. at a much lower dose than is required during systemic 
administration. Combined with the current studies, these obser-
vations establish brain’s inherent capacity to induce dramatic, 
insulin-independent glucose lowering and provide a compelling 
rationale for investigation into underlying mechanisms and their 
clinical relevance. The question of whether centrally active medi-
ators other than leptin and FGF19 can increase GE is also rele-
vant. For example, FGF21 exerts antidiabetic effects analogous 
to those induced by FGF19, and both hormones appear to signal 
via the same receptor (FGFR1), but whether FGF21 increases GE 
is unstudied. In addition to candidate peptides, an increase of 
circulating glucose levels is itself well known to increase GE, and 
the possibility that this involves an effect of glucose in the brain 
is consistent with available data (36).
The contribution made by insulin-independent mechanisms to 
overall glucose homeostasis is surprisingly large. Available evidence 
suggests that GE accounts for approximately 50% of glucose dis-
posal in humans following an i.v. glucose challenge (in rodents, the 
contribution may be greater), with the remaining 50% attributable 
to the combined effects of insulin action and insulin secretion (1). 
It is noteworthy in this context that, like insulin resistance, reduced 
GE makes an important contribution — perhaps comparable to 
that of insulin resistance — to impaired glucose tolerance and T2D 
in humans (1, 37). Consequently, reduced GE is a strong risk factor 
for the development of T2D (38). Combined with our current find-
ings, the possibility that a central defect contributes to impaired 
GE in obesity-associated metabolic impairment can be considered. 
Related questions of strong translational interest include whether 
defects in CNS sensing or responsiveness to FGF19 or other inputs 
contribute to common clinical disorders of glucose homeosta-
sis and whether interventions that increase GE have therapeutic 
potential in individuals with obesity and diabetes.
As a first step to investigate how FGF19 action in the brain 
increases GE, we measured the increment of plasma lactate 
Figure 5
Hepatic effects of i.c.v. FGF19 in ob/ob mice. Hepatic 
expression of (A) G6Pase and (B) Pepck using real-time 
PCR and (C) liver triglyceride and (D) liver glycogen con-
tent in leptin-deficient ob/ob animals that received daily 
i.c.v. injections of either FGF19 (3 μg) or its vehicle. Data 
represent mean ± SEM. *P < 0.05 vs. i.c.v. vehicle.
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levels that follows a glucose challenge. The rationale for this 
approach begins with evidence published some 40 years ago 
that plasma lactate levels increase following consumption of a 
mixed meal in humans (39). Subsequent studies showed that 
this response results not from lactate absorption from the GI 
tract, but from the uptake of glucose into tissues, followed by 
its metabolism to lactate that is subsequently released into the 
circulation (40, 41). Since the same glucose→lactate metabolic 
response occurs after an i.v. glucose challenge, calories do not 
need to enter the body from the GI tract to elicit this response 
— an increased circulating glucose level is sufficient (15). Inter-
estingly, the effect of either oral or i.v. glucose to increase lactate 
levels is reduced in obese humans (15), as is GE (1). We there-
fore asked (a) whether reduced GE in ob/ob mice is associated 
with blunting of the glucose→lactate response and (b) whether 
FGF19 action in the brain increases GE in part by stimulating 
this process. Our data are consistent with both predictions. We 
found that the plasma lactate level increased rapidly following 
an i.v. glucose challenge in WT mice, whereas lactate levels did 
not increase at all in vehicle-treated ob/ob mice, consistent with 
their markedly reduced GE (by ~70%). In contrast, both GE and 
the plasma lactate response to i.v. glucose increased markedly in 
ob/ob mice receiving i.c.v. FGF19. Together, these findings sup-
port a model in which (a) reduced GE in ob/ob mice results in 
part from a decreased glucose→lactate metabolic response, (b) 
the effect of FGF19 to increase GE involves an increase in this 
response, and (c) the brain mediates this effect of FGF19.
The identification of tissues in which this glucose→lactate 
response occurs in mice awaits further study. In dogs and 
humans, the liver is implicated, and it is notable in this 
context both that liver glucose uptake is insulin indepen-
dent and that the brain plays a fundamental role to regu-
late this process (38). However, our finding that the effect 
of FGF19 to increase GE is not associated with increased 
liver glycogen content in ob/ob mice raises questions regard-
ing whether liver glucose uptake is increased, and both fat 
and skeletal muscle can also metabolize glucose to produce 
lactate that is subsequently released into the circulation 
(42, 43). Additional studies are therefore needed to definitively 
identify the tissue(s) involved.
Although our findings support the hypothesis that the antidia-
betic effects of FGF19 involve a central site of action, we empha-
size that they do not preclude a role for peripheral tissue effects 
as well (8, 44). FGFR1 activation exerts glucose-lowering effects 
in liver as well as both brown and white adipose tissue (11), and 
the beneficial effects of systemic FGF19 on glucose tolerance that 
we observed in ob/ob mice were only partially blocked by central 
FGF receptor blockade. Future studies using targeted disruption 
of FGF receptor signaling in a tissue-specific manner will help to 
clarify the extent to which glucoregulatory effects of FGF19 are 
mediated centrally versus peripherally.
In addition, little is known regarding the neurocircuitry under-
lying central FGF19 action, although our data implicate a mech-
anism independent of melanocortin signaling. This assertion is 
based on our findings that FGF19 failed to induce c-Fos (a marker 
of neuronal activation) in hypothalamic POMC neurons and that 
FGF19 improved glucose tolerance in Mc4r-deficient mice (albeit, 
not to the same extent as was observed in ob/ob mice). Whatever 
the underlying neurocircuitry, convergent lines of evidence that 
implicate activation of FGFR1 in the antidiabetic effects of FGF19 
(and FGF21, as well) (9, 10) and the observation that FGFR1 is 
expressed in key hypothalamic areas implicated in metabolic reg-
ulation (12, 13) support a model in this brain area that mediates 
the increase of GE induced by FGF19. Additional studies are war-
ranted to test this hypothesis.
Whether FGF19 plays a physiological role in glucose homeo-
stasis or diabetes pathogenesis is still largely unstudied. Also of 
interest is the as yet untested hypothesis that beneficial meta-
bolic effects of bariatric surgical procedures are tied to increased 
FGF19 secretion from gut enterocytes. Consistent with this 
possibility, circulating levels of bile acids (45, 46) and FGF19 
increase following roux-en-Y gastric bypass (RYGB) surgery in 
humans (47, 48). As bile acid stimulation of FGF19 secretion 
is mediated via FXR, these data collectively raise the possibility 
that increased bile acid–induced stimulation of FGF19 secre-
tion (and increased GE) contributes to the high rate of diabe-
tes remission induced by RYGB (49), but a direct test of this 
hypothesis is still awaited.
In conclusion, our findings suggest that the glucose-lowering 
effect of systemic FGF19 involves a novel central mechanism 
whereby insulin-independent glucose disposal is rapidly, potently, 
and selectively increased. The finding that the brain has the inher-
ent ability to lower blood glucose levels via such a mechanism 
opens new potential avenues for diabetes drug discovery.
Figure 6
Central targets of FGF19 action. (A and B) Immunodetection of POMC (green) and the colocalization of c-fos in POMC neurons in Pomc-Tau-GFP 
mice treated with i.c.v. administration of either (A) vehicle or (B) FGF19 (original magnification, ×20; Scale bar: 20 μm). (C) Glucose tolerance 
(0.5 g/kg) and (D) the integrated area under the glucose curve in Mc4r–/–mice that received a single, acute i.c.v. injection of FGF19 (3 μg) or its 
vehicle. Data represent mean ± SEM. *P < 0.05 vs. i.c.v. vehicle. 3V, third ventricle.
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Methods
Animals. All animals were housed individually under specific patho-
gen–free conditions in a temperature-controlled room with a 12-hour 
light/12-hour dark cycle. Animals were provided with ad libitum access 
to water and standard laboratory chow (PMI Nutrition International 
Inc.) unless otherwise stated. Adult, male ob/ob mice on the C57/Bl6 
background and their WT littermates were obtained from The Jackson 
Laboratory. To better identify POMC cells, we used Pomc-Tau-eGFP 
mice that were provided to us by Tomas Horvath at Yale University (New 
Haven, Connecticut, USA), in which T-topaz GFP is expressed under the 
transcriptional control of the POMC promoter and backcrossed onto 
the C57/Bl6 background for >10 generations (50). Mc4r–/– mice, origi-
nally derived as discussed in ref. 51, were obtained from breeding colo-
nies maintained at the University of Washington.
Surgery. Animals underwent cannulation of the lateral ventricle (Plas-
tics One) under isoflurane anesthesia at stereotaxic coordinates based on 
the brain atlas of Paxinos and Watson (52): –0.7 mm posterior to bregma; 
1.3 mm lateral, and 1.3 mm below the skull surface. The cannula was 
permanently fixed to the skull using glass ionomer cement (Instech Solo-
mon) and was closed with an obturator. Animals received buprenorphine 
hydrochloride (Reckett Colman Pharmaceuticals) at the completion of the 
surgery and were allowed to recover for at least 5 days while food intake 
and body weight were recorded. i.c.v. injections were administered using a 
(33-gauge) needle that extended 1 mm beyond the tip of the cannula over a 
period of 60 seconds in a final volume of up to 1.5 μl. The injector was then 
allowed to remain in place for an addition 60 seconds before removal. For 
studies involving a FSIGT, adult male C57/Bl6 and ob/ob mice underwent 
lateral ventricular cannulation as above as well as catheterization of both 
the carotid artery and jugular vein, as described in detail previously (53).
Body composition analysis. Liver triglyceride content and measures of total 
fat and lean body mass were determined using quantitative magnetic 
resonance spectroscopy (EchoMRI 3-in-1 Animal Tissue Composition 
Analyzer; Echo Medical Systems) using the Energy Balance and Glucose 
Metabolism Core of the Nutrition Obesity Research Center at the Univer-
sity of Washington. Liver glycogen levels were determined using a colorim-
etric assay (Biovision) and were standardized to grams wet weight.
i.p. glucose tolerance testing.  i.p. glucose tolerance tests (ipgtt; 30% d-glucose; 
0.5 or 1.5 g/kg) were conducted in 5-hour fasted animals. Blood glu-
cose levels were measured at t = 0, 15, 30, 60, 90, and 120 minutes using 
a hand-held glucometer (Accu-Chek) to test blood obtained from tail 
capillary samples.
CNS FGF receptor signaling in the glucose-lowering effects of FGF19 in 
ob/ob mice. To determine whether increased FGF19 signaling in the 
brain is sufficient to improve glucose tolerance, adult male ob/ob mice 
were matched for body weight, food intake, and blood glucose levels 
and fasted at 09:00. At 11:30, animals received a single, acute i.c.v. injec-
tion of either vehicle (0.9% saline) or FGF19 (Phoenix Pharmaceuticals) 
at a dose of 1 μg or 3 μg. At 13:00, animals were subjected to an ipgtt 
(0.5 g/kg). Animals followed the same paradigm as described above, 
except that they received an i.p. injection of FGF19 at the same doses 
as administered i.c.v.
To determine whether the glucose-lowering effect of FGF19 involves 
activation of FGF receptors in the CNS, a separate cohort of ob/ob mice 
was matched for body weight, food intake, and blood glucose levels and 
fasted at 09:00. Ninety minutes later, animals received either an i.c.v. pre-
injection of the FGFR inhibitor, PD173074 (Sigma-Aldrich; 25 μg), or its 
vehicle (100% DMSO). Relative to vehicle-treated controls, this dose had 
no effect by itself on either fasting blood glucose levels or glucose tol-
erance (data not shown). To confirm that the glucose-lowering effect of 
i.c.v. FGF19 is receptor mediated, animals received an i.c.v. injection of 
FGF19 (3 μg) or its vehicle 1 hour after pretreatment injection. At 13:00, 
animals were then subjected to an ipgtt (0.5 g/kg). Once the efficacy 
of the inhibitor was validated against i.c.v. FGF19, we asked whether 
pretreatment blunts the antidiabetic effect of FGF19 following systemic 
administration at a higher dose. Adult male ob/ob mice followed the 
same protocol as described above, except that they received a systemic 
(rather than i.c.v.) injection of FGF19 (1 mg/kg).
To determine whether the glucose-lowering effects of i.c.v. FGF19 require 
melanocortin signaling, adult male Mc4r–/– mice bred onto the C57BL/6 
background and matched for age, body weight, and blood glucose were 
subjected the above protocol, in which an ipgtt (1.5 g/kg) was performed 
90 minutes following i.c.v. injection of FGF19 (3 μg) or its vehicle.
Effect of chronic i.c.v. FGF19 on blood glucose levels in ob/ob mice. To deter-
mine whether chronic i.c.v. administration of FGF19 ameliorates 
diabetes in ob/ob mice, adult male ob/ob mice matched for body weight, 
food intake, and blood glucose levels received daily i.c.v. injections of 
FGF19 (3 μg) or its vehicle for 5 consecutive days. Body weight, food 
intake, and blood glucose levels were recorded daily. At the completion 
of the study, animals were perfused, and brains removed and processed 
for immunohistochemical outcomes, as described below. To determine 
whether the glucose-lowering effects of CNS FGF19 could be explained by 
leakage into the periphery, a similar paradigm was used, except that ob/ob 
mice received daily peripheral injections of FGF19 (3 μg) or its vehicle at 
the same dose that was administered i.c.v.
FSIGT. A FSIGT was performed in 5-hour fasted ob/ob mice or their litt-
ermate controls at least 5 days following LV cannulation and arterial and 
venous catheterization. Blood sampling was performed via the arterial 
catheter in unrestrained, conscious animals. A baseline fasted blood sample 
was taken at –10 and 0 minutes. Based on a previous protocol (2), a 1 g/kg 
bolus of 50% dextrose was injected i.v. over a period of 15 seconds at t = 0 
minutes. Blood (20 μl) was sampled for measurement of glucose and sub-
sequent assay of plasma insulin at time points 1, 2, 4, 8, 12, 16, 20, 30, and 
60 minutes. Additional samples were obtained for glucose measurement 
alone at 3, 5, 6, 10, 14, 18, 25, 40, and 50 minutes. Throughout the entire 
procedure, beginning at –10 minutes, mice received i.v. infusion of saline-
washed erythrocytes (5 μl/min) to prevent the significant fall in hematocrit 
that would otherwise occur. Blood glucose levels were measured on a hand-
held glucometer (Accu-Chek).
Minimal model analysis of FSIGT data. Based on glucose and insu-
lin curves, glucose disposal was divided into 3 phases: mixing phase 
(0–2 minutes), GE-dominated phase (2–5 minutes), and insulin-domi-
nated phase (5–60 minutes) (2). The mixing phase was not used for Si 
or GE modeling. Acute insulin response to glucose was based on insulin 
values between 0 and 4 minutes. All Si calculations are multiplied by 104. 
Data were modeled using MinMod software modified for phase dura-
tions as stated above and GE starting estimate.
Effect of i.c.v. FGF19 on c-fos induction in Pomc-Tau-eGFP mice. To deter-
mine whether FGF19 activates POMC neurons in the hypothalamus, 
female Pomc-Tau-eGFP mice underwent lateral ventricular cannulation, 
as described previously. Following a 1-week recovery period, habituated 
animals were fasted for 3-hours and then received an i.c.v. injection of 
either saline or FGF19 (3 μg). Ninety minutes later, mice were perfused, 
with brains removed and processed for immunohistochemical out-
comes, as described below.
Tissue collection and processing. For immunohistochemical studies, mice 
were anesthetized with ketamine/xylazine and perfused with PBS followed 
by 4% PFA in 0.1 M PBS. Brains were removed, post-fixed in 4% PFA over-
night, embedded in 25% sucrose solution for 48 hours at 4°C, snap frozen 
in isopentane, and cooled with liquid nitrogen. The hypothalamus was 
sectioned at 14 μM in the coronal plane using a freezing cryotome, slide-
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using the commercially available PCR Master Mix (SYBR Green, Applied 
2.0; Applied Biosystems) and analyzed as previously described (22, 26).
Statistics. All results are expressed as mean ± SEM. Statistical analyses 
were performed using Statistica (version 7.1). A 1-way analysis of variance 
with a LSD post-hoc test was used to compare mean values among mul-
tiple groups using log-transformed data when Bartlett’s test for unequal 
variance showed P < 0.05, and a 2-sample unpaired Student’s t test 
was used for 2-group comparisons. In all instances, probability values 
of < 0.05 were considered significant.
Study approval. All procedures were performed in accordance with NIH 
guidelines for the care and use of animals and were approved by the Insti-
tutional Animal Care and Use Committee at both the University of Wash-
ington and Vanderbilt University.
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mounted, and stored at –80°C until selection for immunohistochemical 
staining or visualization of GFP by fluorescence microscopy.
Double-label immunofluorescence. For colocalization studies, anatomically 
matched sections throughout the hypothalamus were selected for stain-
ing. Briefly, slides were washed with 10 mM PBS at room temperature 
and were then blocked for 30 minutes with buffer containing 5% normal 
donkey serum, 0.1% BSA, and 0.01% Triton-X in 10 mM PBS. Following 
additional washes, slides were incubated overnight at 4°C in a “cocktail” 
of primary antibodies, including goat polyclonal anti-GFP (Fitzgerald 
Industries) diluted 1:10,000 with rabbit polyclonal anti–c-Fos (Oncogene 
Research Products) diluted 1:100,000. Slides were washed with PBS and 
then incubated for 120 minutes at room temperature with the secondary 
antibodies (a) 1:1,000 donkey anti-goat IgG-Alexa Fluor 488 (Life Tech-
nologies) and (b) 1:1,000 donkey anti-rabbit Alexa Fluor 594 (Life Tech-
nologies), diluted in 5% normal donkey serum and 0.1% BSA in 10 mM 
PBS. After washing with PBS, slides were subsequently coverslipped with 
an antifade aqueous mounting media. Control sections were incubated 
with normal serum and did not show staining.
Plasma analysis. Blood samples for measures of insulin, lactate, and FFAs 
were collected in EDTA-treated tubes, while blood for glucagon assay was 
collected on tubes containing 10 μl of 1 M benzamidine and 1 U of hepa-
rin. Blood was centrifuged and plasma was removed, aliquoted, and stored 
at –80°C. Plasma immunoreactive insulin levels were determined by ELISA 
(Crystal Chem), FFA levels were determined using a colorimetric assay 
(Wako Chemicals), plasma lactate levels were determined using a GM9D 
glucose direct analyzer (Analox Instruments), and plasma glucagon levels 
were determined using a glucagon RIA kit (Linco Research).
RT-PCR. Total RNA was extracted from liver using TRIzol B accord-
ing to manufacturers’ instructions (MRC). RNA was quantitated by 
spectrophotometry at 260 nm (Nanodrop 1000, Thermo Scientific) and 
reverse-transcribed with AMV reverse transcriptase (1 μg) (Promega). Real-
time PCR was performed on a ABI Prism 7900 HT (Applied Biosystems) 
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